Completed PHASE2 INTERVENTIONAL NCT00097955

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Sponsor: Novartis Pharmaceuticals

Interventions aliskiren

Updated 6 times since 2017 Last updated: May 15, 2017 Started: Oct 31, 2004 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00097955, this PHASE2 trial focuses on Diabetic Nephropathy and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Bucharest, Romania , East Hanover, United States , Hillerød, Denmark , Investigative Centers, Germany , London, United Kingdom , Madrid, Spain , Moscow, Russia , Paris, France , Québec, Canada and 2 more locations